#75 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians managing patients with non-alcoholic fatty liver disease may benefit from understanding emerging preclinical evidence on cannabinoids, as CBD and CBG show potential hepatoprotective effects that could inform future treatment discussions and clinical trials. This research is particularly relevant for geriatric populations and patients with metabolic syndrome, where fatty liver disease represents a growing clinical burden and current treatment options remain limited. However, clinicians should recognize this as early-stage research requiring further human trials before recommending cannabinoid-based interventions as standard care.
A recent study published in Age and Ageing examined the potential therapeutic effects of cannabidiol (CBD) and cannabigerol (CBG) on fatty liver disease in older adults, finding that these cannabinoids may help reduce hepatic fat accumulation and improve liver function markers. The research suggests that CBD and CBG could work through anti-inflammatory and antioxidant mechanisms to mitigate liver injury, which is particularly relevant given the rising prevalence of non-alcoholic fatty liver disease across aging populations. These findings have direct implications for clinicians treating older patients with metabolic syndrome or obesity-related liver complications, as cannabinoid-based interventions could potentially offer an adjunctive therapeutic option beyond current standard care. However, clinicians should note that further clinical trials with larger sample sizes and longer follow-up periods are needed before recommending CBD or CBG as a primary treatment strategy. The pharmacokinetic variability and lack of standardized dosing guidelines for these cannabinoids in liver disease populations remain significant barriers to clinical implementation. Clinicians considering cannabis-derived products for patients with fatty liver disease should counsel patients on the preliminary nature of this evidence while monitoring liver function tests if use is pursued.
“What we’re seeing in the emerging research on cannabinoids like CBD and CBG is a genuine pharmacological signal in metabolic disease, particularly nonalcoholic fatty liver disease, which means we need to stop dismissing these compounds and start designing rigorous clinical trials to understand dosing, duration, and which patients benefit most rather than waiting another decade for consensus.”
? While emerging preclinical evidence suggests cannabidiol and cannabigerol may have hepatoprotective properties against fatty liver disease, clinicians should recognize that in vitro and animal model findings do not yet translate reliably to human therapeutic efficacy. Current evidence in human subjects remains limited, and the long-term safety profile of cannabis-derived cannabinoids in patients with existing liver disease—who may have altered drug metabolism—is incompletely characterized. Additionally, cannabis products vary considerably in cannabinoid content and purity, and many are unregulated, creating uncertainty about what patients actually consume. Rather than recommending cannabis for non-alcoholic fatty liver disease at this time, providers should continue to emphasize established interventions such as weight loss, metabolic disease management, and alcohol avoidance, while staying informed about clinical trials that may eventually clarify whether specific cannabinoids offer genuine benefit in this population.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
